Why This Study Is a Big Step Forward in the Fight Against Diabetes
Xeris Pharmaceuticals shares pushed higher on Tuesday after the firm announced positive topline results from its midstage study in adults with Type 1 diabetes mellitus.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 75
Why This PNH Study Could Set the Standard for Treatment
Apellis Pharmaceuticals shares jumped on Tuesday after the firm announced positive results from its late stage study in adults with paroxysmal nocturnal hemoglobinuria (PNH). Specifically, the data came from the Phase 3 Pegasus study…
The Top Biotech ETFs to Watch in 2020
On a company by company basis, investing in biotechs is somewhat tricky. However, there is an investment strategy that makes it much easier.
Is Pfizer Raising Drug Prices Too Much in 2020?
Ahead of election years, the cost and future of health care has become one of the top debates for better than two decades now. Most politicians say that they want to lower prescription drug…
The Top Biopharma Events to Watch in 2020
Here, 24/7 Wall St. presents a calendar of a few of the biggest clinical trial and FDA updates to watch for in early 2020.
Why This Hairy Cell Leukemia Treatment Could Be Big in Europe
Innate Pharma shares jumped on Thursday after the firm announced that the European Medicines Agency has accepted the Marketing Authorization Application for Lumoxiti for adult patients with relapsed or refractory hairy cell leukemia.
Why This Refractory Angina Treatment Could Be a Big Hit
Neovasc shares nearly doubled on Tuesday after the firm announced the submission of an application to the FDA for its Neovasc Reducer medical device for the treatment of refractory angina.
Is It Over for This Huntington’s Disease Clinical Trial?
Wave Life Sciences shares dropped sharply to start out the week after the company announced topline data from its ongoing midstage trial in Huntington’s disease.
Why One Analyst Sees Sarepta’s Roche Deal Taking Off
Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this…
Why This aPAP Treatment Is a Big Hit
Savara shares more than doubled on Monday after the firm announced that the FDA has granted Breakthrough Therapy designation for its autoimmune pulmonary alveolar proteinosis treatment Molgradex.
AstraZeneca’s FDA Nod Could Be Big
AstraZeneca has announced that the FDA has approved its companion diagnostic test that identifies patients with metastatic pancreatic cancer.
Why This Uriniary Tract Infection Trial Could Be Huge
Iterum Therapeutics shares more than doubled on Friday after the firm announced that it had completed the enrollment of its late-stage clinical trial in uncomplicated urinary tract infections.
Why This Osteoarthritis Treatment Is Making Waves
Flexion Therapeutics shares popped on Friday after the company announced that the FDA has approved a supplemental New Drug Application to update the product label for Zilretta for the treatment of osteoarthritis knee pain.
The Top Healthy Living ETFs of 2019
Eating a nutritious and well-balanced diet, exercising regularly and abstaining from bad habits like smoking greatly increase one’s odds of living a long and healthy life. With these trends gaining ever more traction, they…
Could This Breast Cancer Study Be the Next Big Thing?
Immunomedics shares made a handy gain on Thursday after the company announced that the FDA has accepted its Biologics License Application for its breast cancer treatment.